
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 5/1/24**
(See policy history boxes for previous effective dates)

Title: Peroral Endoscopic Myotomy for Treatment of Esophageal Achalasia or Gastroparesis

Description/Background

Esophageal Achalasia

Esophageal achalasia is characterized by reduced numbers of neurons in the esophageal myenteric plexuses and reduced peristaltic activity, making it difficult for patients to swallow food and possibly leading to complications such as regurgitation, coughing, choking, aspiration pneumonia, esophagitis, ulceration, and weight loss. The estimated U.S. prevalence of achalasia is 10 cases per 100,000, and estimated incidence is 0.6 cases per 100,000 per year.¹

Treatment

Treatment options for achalasia have included pharmacotherapy (e.g., injections with botulinum toxin), pneumatic dilation, and laparoscopic Heller myotomy.^{1, 2} Although the latter two are considered the standard treatments because of higher success rates and relatively long-term efficacy compared with pharmacotherapy, both are associated with a perforation risk of about 1%. Laparoscopic Heller myotomy is the most invasive of the procedures, requiring laparoscopy and surgical dissection of the esophagogastric junction.² One-year response rates of 86% and major mucosal tear rates requiring subsequent intervention of 0.6% have been reported.³

Peroral endoscopic myotomy (POEM) is a novel endoscopic procedure developed in Japan.^{2,4} This procedure is performed with the patient under general anesthesia.⁵ After tunneling an endoscope down the esophagus toward the esophageal-gastric junction, a surgeon performs the myotomy by cutting only the inner, circular lower esophageal sphincter (LES) muscles through a submucosal tunnel created in the proximal esophageal mucosa. POEM differs from laparoscopic surgery, which involves the complete division of both circular and longitudinal LES muscle layers. Cutting the dysfunctional muscle fibers that prevent the LES from opening allows food to enter the stomach more easily.^{2,5}

Gastroparesis

Gastroparesis is characterized by symptoms of nausea, vomiting, bloating, early satiety, and pain, which is caused by delayed gastric emptying without mechanical obstruction.⁶ The estimated U.S. prevalence of difficult to ascertain due to the weak correlation of symptoms with gastric emptying which results in a high rate of underdiagnosis. Using data from 1996 to 2006, the estimated incidence per 100,000 persons, adjusted for age, was 9.6 for men and 37.8 for women.

Treatment

Treatment options for gastroparesis have included dietary modification (smaller meal sizes, avoidance of carbonated beverages, smoking or high doses of alcohol, and in some cases enteral nutrition via jejunostomy), optimization of hydration and glycemic control, pharmacotherapy (e.g., antiemetics or Metoclopramide, or off-label medications for symptom control such as domperidone, erythromycin, tegaserod or centrally acting antidepressants), gastric electrical stimulation, venting gastrostomy, feeding jejunostomy, intra-pyloric botulinum injection, partial gastrectomy, and pyloroplasty.⁶ Gastric peroral endoscopic myotomy (G-POEM), which endoscopically performs the equivalent of pyloroplasty, is being investigated for the treatment of gastroparesis. G-POEM myotomizes the pylorus rather than the circular LES but otherwise consists of the same techniques described above.

Regulatory Status

POEM uses available laparoscopic instrumentation and, as a surgical procedure, is not subject to regulation by the U.S. Food and Drug Administration.

Medical Policy Statement

Peroral endoscopic myotomy (POEM) as a treatment for pediatric and adult esophageal achalasia or gastroparesis is experimental/investigational. It has not been scientifically demonstrated to be as safe and effective as conventional treatment.

Inclusionary and Exclusionary Guidelines

N/A

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

N/A

Other codes (investigational, not medically necessary, etc.):

43499

43497

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, two domains are examined: the relevance, the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effect. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

PERORAL ENDOSCOPIC MYOTOMY FOR ADULT PATIENT WITH ACHALASIA

Clinical Context and Therapy Purpose

The purpose of peroral endoscopic myotomy (POEM) in individuals who have esophageal achalasia is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following **PICOs** were used to select literature to inform this review.

Populations

The relevant population of interest are patients with esophageal achalasia. Esophageal achalasia is characterized by reduced numbers of neurons in the esophageal myenteric plexuses and reduced peristaltic activity, making it difficult for individuals to swallow food and possibly leading to complications such as regurgitation, coughing, choking, aspiration pneumonia, esophagitis, ulceration, and weight loss.

Interventions

The therapy being considered is POEM. The POEM procedure involves tunneling an endoscope down the esophagus toward the esophageal-gastric junction. A surgeon performs the myotomy by cutting only the inner, circular lower esophageal sphincter (LES) muscles through a submucosal tunnel created in the proximal esophageal mucosa.

Patients receive general anesthesia during the POEM procedure, which is conducted in tertiary care facilities.

Comparators

Comparators of interest include esophageal dilatation, and laparoscopic Heller myotomy (LHM), and botulinum toxin injection.

Esophageal dilation is performed in a graded approach, starting with a small balloon (typically 30mm), then progressing to larger balloons (35-40mm) two to four weeks later. The balloons are placed at the level of the gastroesophageal junction and inflated slowly, in order to tear the muscle fibers in a controlled manner. Esophageal perforations are a potential complication. Long-term studies have estimated that approximately one-third of patients may need a repeat procedure.

Heller laparoscopic myotomy is a minimally invasive procedure in which the thick muscle of the lower esophagus and the upper stomach is cut to open the tight LES. The procedure involves five small incisions to insert the camera and surgical instruments. Reported success rates are high (>90%), with a five-year follow-up study showing an 8% rate of symptom recurrence.

Endoscopic botulinum toxin is injected with a sclerotherapy needle approximately 1 cm above the esophagogastric junction. The complication rate is low and approximately 80% of patients experience immediate symptom relief. The effect diminishes over time, with more than 60% of patients reporting recurrent symptoms at one year.

Outcomes

The general outcomes of interest are symptom relief and treatment-related morbidity.

Symptom relief may be measured by Eckardt score, which is comprised of four major symptoms of achalasia: dysphagia, regurgitation, retrosternal pain, weight loss. Each symptom receives a score from 0 (none) to 3 (severe), for a maximum score of 12. Total scores of four or greater represent treatment failure.⁶

A treatment-related morbidity of concern is the development of gastroesophageal reflux disease (GERD). GERD risk is high with this procedure because POEM involves ablating the LES without adding any type of anti-reflux mechanism. Additional complications include thoracic effusion, subcutaneous emphysema, and esophagitis.

Symptom relief may be experienced shortly following the procedure. Assessment of durability of relief requires a follow-up of months to years of follow-up.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse effects, single-arm studies that capture longer periods of follow-up and/or larger populations were sought;
- Studies with duplicative or overlapping populations were excluded.

Systematic Reviews

Multiple systematic reviews and meta-analyses have been published to evaluate POEM as a treatment for achalasia. They are heterogenous in whether they assessed data on POEM alone or compared POEM to LHM, which outcomes they assessed, which studies they included, and in the statistical methods they used. The majority addressed the comparison of POEM to LHM. No systematic review has included either of the 2 published RCTs summarized below.

Results of systematic reviews that primarily relied on data from noncomparative case series studies are not comprehensively summarized herein.^{8,9,10,11,12} This is because conclusions on comparative effects cannot be determined from their findings. Some systematic reviews of noncomparative case series did not calculate comparative treatment effects. Others that did had important limitations in their statistical methods, including use of unadjusted indirect comparison approaches which are subject to a variety of confounding factors that may bias the effect estimate. For example, Aiolfi et al (2019) published a meta-analysis of success rates based on manometric subtypes.¹¹ They calculated pooled success rates for POEM, LHM, and PD in type I, II, and III achalasia, respectively, based primarily on data from noncomparative case series studies. Pooled success rates for POEM in types I, II, and III were 94% (95% confidence interval [CI], 89% to 98%), 97% (95% CI, 93% to 99%), and 93% (95% CI, 88% to 97%), respectively, which were significantly higher than compared to LHM for type I (odds ratio [OR]=2.97; 95% CI, 1.09 to 8.03) and type III (OR=3.50; 95% CI, 1.39 to 8.77), but not type II. However, the use of an unadjusted indirect comparison approach in this analysis precludes drawing conclusions based on these findings.

Peroral Endoscopic Myotomy Versus Laparoscopic Heller Myotomy or Pneumatic Dilation

Below are summarized the most recent systematic reviews (published on or after 2020) that address the comparison of POEM to LHM or PD using data from comparative observational studies and RCTs. Table 1 provides a crosswalk of the comparative studies included in these systematic reviews.

Table 1. Comparison of Observational Studies of POEM vs. LHM Included in SR & M-A

Study	Dirks et al (2021) ¹² .	Facciorusso et al (2021) ¹³ .	Martins et al (2020) ¹⁴ .	Aiolfi et al (2020) ¹⁵ .
Hungness et al (2013) ⁵ .	●		●	●
Teitelbaum et al (2013) ¹⁷ .			●	●
Ujiki et al (2013) ¹⁸ .	●		●	●
Bhayani et al (2014) ¹⁹ .	●		●	●
Kumagai et al (2015) ²⁰ .	●		●	●
Kumbhari et al (2015) ²¹ .	●			●
Chan et al (2016) ²² .			●	●
Sanaka et al (2016) ²³ .	●		●	

Schneider et al (2016) ²⁴	●		●	
Kashab et al (2017) ²⁵	●		●	
Leeds et al (2017) ²⁶	●			●
de Pascale et al (2017) ²⁷	●		●	
Peng et al (2017) ²⁸	●		●	
Ward et al (2017) ²⁹	●		●	
Hanna et al (2018) ³⁰	●			●
Ramirez et al (2018) ³¹	●			●
Caldaro et al (2015) ³²	●			
Fumagalli et al (2016) ³³	●			
Greenleaf et al (2018) ³⁴	●			
Kim et al (2019) ³⁵	●			
Meng et al (2017) ³⁶	●			
Miller et al (2017) ³⁷	●			
Ponds et al (2019) ³⁸	●	●		
Sanaka et al (2019) ³⁹	●			
Wang et al (2016) ⁴⁰	●			
Werner et al (2019) ⁴¹	●	●		
Wirsching et al (2019) ⁴²	●			
Zheng et al (2019) ⁴³	●			
Podboy et al (2020) ⁴⁴	●			
Tan et al (2016) ⁴⁵	●			
Boeckxstaens et al (2011) ⁴⁶		●		
Borges et al (2014) ⁴⁷		●		
Kostic et al (2007) ⁴⁸		●		
Hamdy et al (2015) ⁴⁹		●		

POEM: Peroral Endoscopic Myotomy; LHM: Laparoscopic Heller Myotomy; SR: systematic review; M-A: meta-analysis

Tables 2 and 3 summarize characteristics and results of the included systematic reviews published ≥ 2020 that address the comparison of POEM to LHM using data from comparative observational studies. The included comparative observational studies are heterogenous in their patient populations, proportions of patients with any previous treatments (i.e., none versus prior pneumatic dilation or botulinum toxin, or prior pneumatic dilation and botulinum toxin), and proportions of each achalasia subtype I-III, follow-up duration, and definition of treatment success. These differences limit interpretation of their findings.

Dirks et al (2021) conducted a systematic review and meta-analysis that evaluated the efficacy and safety of POEM in comparison to LHM and PD.¹³ The review included 28 studies (2 RCTs [Ponds et al (2019)³⁸, and Werner et al (2019)⁴¹]; 26 observational studies). Most comparative studies on POEM included LHM (n=21), with a minority involving POEM versus PD (n=8). One study included all 3 interventions. Since POEM is a relatively new intervention, studies evaluating POEM often had shorter follow-up. Two studies included children, with 1 each comparing POEM to PD and LHM. The majority of included studies had a baseline achalasia subtype that was either predominantly type 2 and/or type 1; only 1 study had predominantly type 3 achalasia. The vast majority of included studies had <100 total patients. Results revealed POEM to have similar efficacy to LHM. However, POEM treated dysphagia better than PD in a RCT and observational studies and POEM needed reintervention less than PD in a RCT (risk ratio [RR] 0.19; 95% CI, 0.08 to 0.47) and LHM in an observational study (RR 0.33; 95% CI, 0.16 to 0.68). POEM had similar safety outcomes to LHM and PD. The authors concluded that POEM has similar outcomes to LHM and greater efficacy than PD.

Facciorusso et al (2021) completed a systematic review and network meta-analysis of first-line therapeutic interventions for achalasia.¹⁴ The review included 6 RCTs in adults with achalasia that compared the efficacy of PD (n=260), LHM (n=309) and POEM (n=176). Four trials compared LHM with PD, 1 compared POEM to PD, and 1 compared POEM with LHM. Overall, low-quality evidence, based primarily on direct evidence, supported the use of POEM over PD for treatment success at 1 year while there was no significant difference observed between LHM and POEM. Severe esophagitis occurred at an incidence of 5.3%, 3.7%, and 1.5% for POEM, LHM, and PD, respectively. Procedure-related serious adverse events after POEM, LHM, and PD were 1.4%, 6.7%, and 4.2%, respectively. The authors concluded that POEM and LHM have comparable efficacy and may increase treatment success as compared to PD, with low confidence in estimates.

Martins et al (2020) conducted a systematic review and meta-analysis of the largest number of comparative observational studies and patients treated with POEM (n=359) or LHM (n=534).¹⁵ Study quality was assessed using the Modified New Castle Ottawa Scale and all included studies were considered to be adequate for analysis. POEM demonstrated small improvements in Eckardt scores and reduced length of stay, comparable operative time, but more major adverse events. Most of the major adverse events were described as being related to unrecognized intraoperative mucosal perforation. An important limitation of this meta-analysis is that it did not take into account between-group differences in pre-operative Eckardt score levels at baseline.

Aiolfi et al (2020) conducted a systematic review and Bayesian random-effects network meta-analysis that compared POEM to LHM and pneumatic dilation.¹⁶ Overall, 19 studies of 4407 patients were included. Of those, 10 studies of 645 patients directly compared POEM and LHM and none directly compared POEM and pneumatic dilation. POEM was associated with improved dysphasia remission and Eckardt scores, but higher risk of GERD compared to LHM. Results of the comparison to pneumatic dilation are discussed below Table 3. Important limitations of this network meta-analysis include its inclusion of arm-based indirect comparisons and the inherent bias of its reliance on observational studies.

Table 2. SR & M-A Characteristics

Systematic Review	Dates	Included Comparative Studies	Participants	N (Range)	Design	Duration
Dirks et al (2021)	2010-2019	28	Adult and pediatric patients with achalasia	2339 (15 to 241)	26 observational; 2 RCTs	Follow-up: ≥ 2 months to 5.4 years; most studies had <2 year follow-up
Facciorusso et al (2021)	Through Dec 2019	6	Adults with achalasia	745 (50 to 221)	RCTs	Minimum follow-up of 1 year; range: 1 to 5 years
Martins et al (2020)	2012-2017	12	All adult patients (≥ 18 years of age) with 1 of 3 subtypes of achalasia, with or without prior history of therapy for achalasia	893 (31 to 178)	Observational	9 to 260 weeks
Aiolfi et al (2020)	2012-2018	10	Esophageal achalasia	645 (23 to 101)	Observational	NR

SR: systematic review; M-A: Meta-Analysis; N: sample size; NR: Not reported

Table 3. SR & M-A Results

Systematic Review	Dysphasia	Eckardt Score/Treatment Success	GERD	Length of Hospital Stay	Overall major / severe adverse events
Dirks et al (2021)					
POEM vs. LHM; Pooled effect (95% CI)		RCT (success by Eckhardt score): 83% vs. 82%; RR, 1.02 (0.9 to 1.15)	RCT (severe reflux esophagitis): 4.6% vs. 6.4%; RR, 0.73 (0.20 to 2.58)	RCT (mean): 2.9 vs. 3.2; MD, -0.3 (-0.67 to 0.07)	RCT (treatment-related serious adverse events): 3% vs. 7%; RR, 0.32 (0.9 to 1.17)
POEM vs. PD Pooled effect (95% CI)		RCT (success by Eckhardt score): 92% vs. 54%; RR, 1.71 (1.34 to 2.17)	RCT (severe reflux esophagitis): 6% vs. 0%; RR, 3.82 (0.20 to 71.48)		RCT (treatment-related serious adverse events): 0% vs. 1.6%; RR, 0.19 (0.08 to 0.47)
Facciorusso et al (2021)					
POEM vs. LHM RR (95% CI)		Treatment success at 1 year: no significant			

		difference observed			
		Treatment success at 2 years: RR, 1.02 (0.90 to 1.15)			
POEM vs. PD RR (95% CI)		Treatment success at 1 year: RR, 1.29 (0.99 to 1.69)			
		Treatment success at 2 years: RR, 1.76 (1.37 to 2.25)			
Martins et al (2020):					
Total N	N/A	249	354	451	Total N
Pooled effect (95% CI)	NR	MD, -0.257 (-0.512 to -0.002)	RD, 0.00 (-0.09 to 0.09) I ² : 0%	MD, -0.6 (-1.11 to -0.09) I ² =70%	"Major events (CD III a and IIIb) were more common in the POEM group"; analysis NR
Aiolfi et al (2020)					
Total N	NR	NR	NR	N/A	N/A
Pooled effect (95% CI)	Remission RR, 1.21 (1.04 to 1.47) I ² =0.0%	MD, -0.6 (-1.4 to -0.2) I ² =17.5%	RR, 1.75 (1.35 to 2.03) I ² =6.3%	NR	NR

CD: Clavien-Dindo; CI: confidence interval; GERD: Gastroesophageal Reflux Disease; LHM: laparoscopic Heller myotomy; MD: Mean Difference; N: sample size; N/A: Not applicable; NR: Not reported; OR=Odds Ratio; POEM: Peroral Endoscopic Myotomy; RD: Risk Difference; RR=Risk Ratio; WMD: weighted mean difference;

Peroral Endoscopic Myotomy Versus Pneumatic Dilatation

Zhong et al (2020) conducted a meta-analysis of 7 observational studies comparing POEM (n=298) to pneumatic dilation (n=321).⁵⁰ Achalasia type varied, with 33% type I, 55% type II, and 12% type III. The mean age of the patients in the included studies ranged from 14 to 69 years; thus, including 2 pediatric studies and 2 studies of older adults. Follow-up ranged from 2 to 49.23 months. POEM improved the clinical success rate (24-month RR=1.35; 95% CI, 1.10 to 1.65; I²=70%) and change in Eckardt scores (MD 1.19, 95% CI 0.78 to 1.60, I²=70%); however, the risk of GERD and other complications was higher for POEM compared with pneumatic dilation (RR=4.17, 95% CI, 1.52 to 11.45, and RR=3.78; 95% CI, 1.41 to 10.16, respectively). Important limitations of this meta-analysis include the inherent bias of reliance on observational studies and the high between-study clinical and statistical heterogeneity.

Aiolfi et al (2020) conducted a systematic review and Bayesian random-effects network meta-analysis that compared POEM to LHM and pneumatic dilation.¹⁶ Overall, 19 studies of 4407 patients were included. Of those, none directly compared POEM and pneumatic dilation.

Therefore, data from the POEM and pneumatic dilation arms of studies that compared them each, respectively, to LHM, were indirectly compared in the network meta-analysis. Compared to pneumatic dilation, POEM was associated with improved dysphasia remission (RR=1.40; 95% CI, 1.14 to 1.79) and Eckardt scores (MD=-1.2; 95% CI, -2.3 to -0.2), but higher risk of GERD (RR=1.36; 95% CI, 1.18 to 1.68). Important limitations of this network meta-analysis include its inclusion of arm-based indirect comparisons and the inherent bias of its reliance on observational studies.

Randomized Controlled Trials

Although included in the 2 most recent meta-analyses, the RCTs by Ponds et al (2019)³⁸ and Werner et al (2019)⁴¹ remain the landmark studies involving POEM. These are described below along with 2 more recent trials which have yet to be included in a review or meta-analysis.^{51,52}

Ponds et al (2019) published a randomized clinical trial comparing POEM and pneumatic dilation for treatment-naïve patients with achalasia.⁴² Between 2012 and 2015, patients from 6 sites in 5 countries were randomized to receive either POEM or pneumatic dilation (Tables 4 and 5). The primary outcome was overall treatment success at 2 years, defined as an Eckardt score < 3 and the absence of severe complications or retreatment. Based on previously reported success rates, the power calculation for the primary outcome was based on a difference of at least 20%. Treatment success at 2 years was significantly higher in the POEM group. However, POEM had higher rates of reflux esophagitis than pneumatic dilation. Two serious adverse events (including one perforation) occurred after pneumatic dilation; no serious adverse events occurred after POEM. The study was limited by the lack of blinding, lack of intention to-treat analysis, and by the follow-up time starting at treatment initiation rather than at randomization.

Werner et al (2019) published a randomized, noninferiority trial that compared POEM to LHM plus Dor's fundoplication in patients with idiopathic achalasia.⁴⁵ The primary outcome was clinical success at 2 years, defined as an Eckardt score < 3, without the use of additional treatments. A noninferiority margin of -12.5 percentage points was prespecified as "clinically acceptable" for the primary end point, based on input from the interventional gastroenterologists and surgeons involved in the trial. Analyses were primarily performed in a modified intention-to-treat population of 221 patients, which excluded 20 (8%) of patients who withdrew consent, had exclusion criteria discovered post-randomization, or did not undergo treatment. Among the modified intention-to-treat population, the mean age was 48.6 years, 64.2% had no previous therapy, 26.2% had a previous endoscopic pneumatic dilation, and their mean Eckardt symptom score was 6.8. POEM was noninferior to LHM plus Dor's fundoplication for clinical success at 2 years, but rates of reflux esophagitis were higher for POEM. This resulted in more patients in the POEM group receiving daily low-dose proton-pump inhibitors at 24 months. Although a higher rate of serious adverse events was reported in the LHM group, the difference was not statistically significant. This was likely owing to insufficient statistical power for measuring differences in rare outcomes. The most common serious adverse event in the LHM group was mucosal perforation (n=3, 2.7%). The RCT was limited by the lack of blinding of outcome assessment.

Table 4. Summary of Key RCT Characteristics

Study	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Ponds et al (2019) ⁴² .	Netherlands, Germany, Italy, Hong Kong	6	2012-2015	Treatment naïve adults with newly diagnosed achalasia and Eckardt score ≥ 3	POEM (n=64)	PD Initial with 30 mm balloon Subsequent with 35 mm balloon if Eckardt score ≥ 3 at 3 weeks (n=66)
Werner et al (2019) ⁴⁵ .	Belgium, Czech Republic, Germany, Italy, Netherlands, Sweden	8	2012-2015	Adults with symptomatic achalasia and Eckardt score ≥ 3	POEM (n=120)	LHM plus Dor's fundoplication (n=121)

POEM: peroral endoscopic myotomy; RCT: randomized controlled trial. LHM: laparoscopic Heller's myotomy;

Table 5. Summary of Key RCT: 2-Year Results

Study	Treatment success, n (%)	PPI use	Endoscopic Reflux Esophagitis	Retreatment	Treatment-related SAE
Ponds et al (2019) ⁴² .	126	92	92	126	126
POEM	58 (92%)	58 Median(IQR) SD 24(41) 6.5	54 No.(%) SD 22(41) 6.5	63 No.(%) SD 5 (8) 3.4	63 No.(%) SD 0
PD	34 (54%)	34 Median (IQR) SD 7(21) 7	29 n (%) SD 2(7) 4.7	63 n (%) SD 26 (41) 10.5	63 n (%) SD 1(1.6) 1.7
Comparative treatment effect (95% CI)	RR, 1.71 (1.34 to 2.17) ^a	AD, 20 (1 to 38) ^a	AD, 34 (12 to 49) ^a	AD, 33 (17 to 47) ^a	AD, 1.6 (-5 to 10) ^a
Werner et al (2019) ⁴⁵ .	221	221	165		221
POEM	93 (83.0)	n (%) 41 (38.7)	n (%) 38 (44)	NR	n (%) 3 (2.7)
LHM	89 (81.7)	n (%) 21 (19.4)	n (%) 23 (29)	NR	n (%) 8 (7.3)
Comparative treatment effect (95% CI)	RR, 1.4 (-8.7 to 11.4) ^a	NR	OR, 2.00 (1.03 to 3.85)	NR	RR, 4.6 (-1.1 to 10.4) ^a

^a Unadjusted Risk Ratio (95% confidence interval[CI])

^b Unadjusted Absolute Difference (95% CI)

^c Odds Ratio (95% CI)

IQR: interquartile range; PPI: proton pump inhibitor; RCT: randomized controlled trial; SAE: severe adverse even; SD: standard deviation.

Tables 6 and 7 summarize the important limitations of the RCTs discussed above.

Table 6. Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Ponds et al (2019) ⁴² ,			2. PD protocol limited to 1 to 2 dilations as compared to clinical practice 2. Optimal comparator would be LHM	4. Eckardt score not validated symptom assessment	
Werner et al (2019) ⁴⁵ ,	4. Non-US		2. LHM plus Dor's fundoplication		

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 7. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Follow-Up ^d	Power ^e	Statistical ^f
Ponds et al (2019) ⁴² ,		1. Blinding not possible due to different technical approaches to each procedure	6. Per protocol analysis	6. Not intent to treat analysis 6. Follow-up insufficient to define long-term effects		3. Inadequate statistical analysis and reporting
Werner et al (2019) ⁴⁵ ,		1. Not blinded outcome assessment				

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^d Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

^f Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Nonrandomized Comparative Studies

Numerous nonrandomized comparative studies have compared POEM and LHM in adults with achalasia. The majority of these studies are included in the systematic reviews described above and will not be comprehensively summarized herein. Those that were not included in previous systematic reviews or that have notable characteristics (*i.e.*, focus on important subpopulations, have long-term follow-up) are summarized below.

Docimo et al (2016) published a retrospective study comparing POEM and LHM for individuals with achalasia that was not included in any above-described systematic review.⁵⁵ Patients who underwent POEM (n=44) or LHM (n=122) between 2006 and 2015 were included. There was no difference in average pain scores for POEM and LHM after the first 24 hours (2.7 ± 2.067 vs. 3.29 ± 1.980 , $p=0.472$) or at time of discharge (1.6 ± 2.420 vs. 2.09 ± 2.157 , $p=0.0657$). The POEM group required significantly fewer less narcotics while hospitalized than the LHM group (35.8mg vs. 101.8mg, $p<0.001$), and fewer POEM patients needed a prescription for a narcotic analgesic at discharge (6.81% vs. 92.4%, $p<0.001$). Also, the average length of stay was 31.2 hours for POEM and 55.79 for LHM ($p<0.001$). The study was limited by its retrospective nature and its lack of randomization and blinding.

Wang et al (2016) retrospectively reviewed outcomes for POEM (n=21) and pneumatic dilation (n=10) in patients ages 65 years and older.⁴⁴ All were treated successfully, with decreases in Eckhardt scores. At a mean follow-up of 21.8 months for POEM and 35 months for pneumatic dilation patients, one POEM case failed, and two pneumatic dilation procedures failed.

In a retrospective study of patients with type III achalasia, Kumbhari et al (2015) compared outcomes for 49 patients who underwent POEM across 8 centers between 2011 and 2013, and a historical control groups of 25 patients who underwent LHM between 2000 and 2013.²⁴ Defining clinical response as a reduction in Eckardt score of no more than 1, clinical response was more frequent in the POEM group (98.0%) than the LHM group (80.8%, $p=.01$). On multivariable analysis, there was no statistically significant difference in the odds of failure between procedures, although the point estimate of the odds favored POEM (odds ratio, 11.32; $p=0.06$). Procedure times were shorter with POEM. There was no difference in length of stay. The overall rate of adverse events was lower in the POEM group (6% vs. 27%, $p=0.01$). However, an important limitation of this study is that LHM patients had a more severe disease at baseline by several different measures (*i.e.*, higher Eckardt symptom stage, prior endoscopic interventions). Also, the LHM and POEM groups differed in the achalasia diagnostic criteria used, with the LHM group lacking use of the current gold standard of high-resolution esophageal manometry to diagnose type III because it was not yet available at that time.

Section Summary: Peroral Endoscopic Myotomy for Adult Individuals with Achalasia

Studies on POEM for adults with achalasia included systematic reviews, nonrandomized studies, and 2 RCTs. Conclusions on comparative efficacy cannot be determined from the systematic reviews because they did not appear to have accounted for differences in patient characteristics in the nonrandomized studies. Findings from RCTs demonstrated that POEM had a similar or greater treatment success rate based on the Eckardt score and similar or fewer adverse events compared with PD or LHM. However, POEM had significantly higher rates of endoscopically confirmed reflux esophagitis. An important conduct limitation of the RCTs is that blinded assessment of outcomes was not used. Given that the primary outcome was based on subjective patient report of symptoms, this is a potential source of bias. Additionally, a potential relevance limitation is that the RCTs did not include any US sites. The nonrandomized studies comparing POEM with other procedures were retrospective and involved patients who might not be comparable in terms of age and severity of the disease. Although outcomes were generally similar between POEM and the comparator treatments (LHM, PD), potential confounding and selection bias makes outcome comparisons uncertain. The comparative studies did not report long-term outcomes.

PERORAL ENDOSCOPIC MYOTOMY FOR PEDIATRIC PATIENTS WITH ACHALASIA

Clinical Context and Therapy Purpose

The purpose of POEM in patients who have esophageal achalasia is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of POEM improve the net health outcome of pediatric patients with esophageal achalasia?

The following **PICOs** were used to select literature to inform this review.

Populations

The relevant population of interest are pediatric patients with esophageal achalasia. Esophageal achalasia is characterized by reduced numbers of neurons in the esophageal myenteric plexuses and reduced peristaltic activity, making it difficult for patients to swallow food and possibly leading to complications such as regurgitation, coughing, choking, aspiration pneumonia, esophagitis, ulceration, and weight loss.

Interventions

The therapy being considered is POEM. The POEM procedure involves tunneling an endoscope down the esophagus toward the esophageal-gastric junction. A surgeon performs the myotomy by cutting only the inner, circular LES muscles through a submucosal tunnel created in the proximal esophageal mucosa.

Patients receive general anesthesia during the POEM procedure, which is conducted in tertiary care facilities.

Comparators

Comparators of interest include esophageal dilatation, and LHM, and botulinum toxin injection.

Esophageal dilation is performed in a graded approach, starting with a small balloon (typically 30 mm), then progressing to larger balloons (35-40 mm) 2 to 4 weeks later. The balloons are placed at the level of the gastroesophageal junction and inflated slowly, in order to tear the muscle fibers in a controlled manner. Esophageal perforations are a potential complication. Long-term studies have estimated that approximately one-third of patients may need a repeat procedure.

Heller laparoscopic myotomy is a minimally invasive procedure in which the thick muscle of the lower esophagus and the upper stomach is cut to open the tight LES. The procedure involves five small incisions to insert the camera and surgical instruments. Reported success rates are high (>90%), with a 5-year follow-up study showing an 8% rate of symptom recurrence.

Endoscopic botulinum toxin is injected with a sclerotherapy needle approximately 1 cm above the esophagogastric junction. The complication rate is low and approximately 80% of patients experience immediate symptom relief. The effect diminishes over time, with more than 60% of patients reporting recurrent symptoms at 1 year.

Outcomes

The general outcomes of interest are symptom relief and treatment-related morbidity.

Symptom relief may be measured by the Eckardt score, which is comprised of four major symptoms of achalasia: dysphagia, regurgitation, retrosternal pain, weight loss. Each symptom receives a score from 0 (none) to 3 (severe), for a maximum score of 12. Total scores of four or greater represent treatment failure.⁹

A treatment-related morbidity of concern is the development of GERD. GERD risk is high with this procedure because POEM involves ablating the LES without adding any type of anti-reflux mechanism. Additional complications include thoracic effusion, subcutaneous emphysema, and esophagitis.

Symptom relief may be experienced shortly following the procedure. Duration of relief is measured after months to years of follow-up.

Systematic Reviews

Zhong et al (2021) published an updated systematic review and meta-analysis evaluating clinical outcomes of POEM for the treatment of achalasia in children.⁵⁶ The review included 11 studies published between January 2009 to June 2020 (N=389; 222 boys). The mean age of the patients ranged from 5.5 to 15.2 years with symptom duration ranging from 1.7 to 26.4 months. The pooled technical success (completion of the POEM procedure successfully) was achieved in 385 children (97.4%; 95% CI, 94.7% to 98.7%) and the pooled clinical success (decrease in Eckardt score to ≤ 3 during follow-up) was achieved in 343 children (92.4%; 95% CI, 89% to 94.8%). The Eckardt score was significantly reduced by 6.76 points following POEM (95% CI, 6.18 to 7.34; $p < .00001$). Regarding adverse events, the pooled major adverse event rate was 12.8% (95% CI, 4.5% to 31.5%) with a pooled gastroesophageal reflux rate of 17.8% (95% CI, 14.2% to 22%). The authors concluded that POEM was effective and safe for treating children with achalasia; however, all included studies in the analysis were observational in nature.

Lee et al (2019) published a systematic review and meta-analysis evaluating POEM for the treatment of pediatric achalasia.⁵⁷ Twelve studies, published between 2013 and 2018, with a total of 146 patients (53.68% female), were included in the analysis. There was a reduction in the Eckardt score of 6.88 points (mean difference 6.88, 95% CI 6.28–7.48, $p < 0.001$) and a reduction in LES pressure of 20.73 mmHg (mean difference 20.73, 95% CI 15.76–25.70, $p < 0.001$). Improvement or resolution of short- and long-term achalasia symptoms was experienced in 93% of patients. The study was limited by several of the including studies being case series (5/12) with no control groups or comparators, all of the studies having a sample size of < 30 , and by most studies only reporting follow-up of ≤ 2 years.

Nonrandomized Comparative Studies

Nabi et al (2019) published a retrospective study assessing POEM for the treatment of children with achalasia.⁵⁸ Forty-four patients ≤ 18 years old and weighing ≥ 10 kg who were diagnosed with achalasia between 2013 and 2018 were included. POEM was successfully performed in 43 patients (technical success 97.72%). Eleven (25.6%) children experienced intra-operative Aes, including retroperitoneal CO₂ (n=7), capnoperitoneum (n=3), and mucosal injury (n=1). Clinical success at 1, 2, 3, and 4 years follow-up was 92.8%, 94.4%, 92.3%, and 83.3%, respectively. The study was limited by its retrospective design, the lack of confirmation of GER in about half the patients, and the small number of patients who completed three or more years of follow-up.

Miao et al (2017) published a retrospective, single-center study of POEM for the treatment of pediatric achalasia.⁵⁹ Twenty-one children (aged 11 months –18 years) diagnosed with achalasia and treated between 2014 and 2016 were included. Mean follow-up time was 13.2 months. No severe Aes were reported, and for all patients, difficulty in feeding or swallowing was significantly alleviated or resolved. By 1 month after POEM, all Eckardt scores were <3 and by 6 months were 0.75 on average (average pre-operative score 7.18; p<0.001). At 6 months, an average weight gain of 2.7kg was observed. Four patients had gastroesophageal reflux and two had concomitant gastroesophageal reflux and reflux esophagitis at three months follow-up. No limitations to the study were reported.

Section Summary: POEM for Pediatric Patients with Achalasia

Two systematic review and meta-analysis available evaluating POEM for the treatment of pediatric achalasia was identified. A significant decrease was observed in both Eckardt scores and LES pressure, as well as improvement in symptoms; however, no RCTs were included and all of the included studies had sample sizes <30. Two comparative studies were available evaluating POEM for the treatment of pediatric achalasia. Both studies reported high rates of success for POEM and alleviation of achalasia symptoms.

PERORAL ENDOSCOPIC MYOTOMY FOR ADULTS OR PEDIATRIC PATIENTS WITH GASTROPARESIS

Clinical Context and Therapy Purpose

The purpose of gastric POEM in patients who have gastroparesis is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of gastric POEM improve the net health outcome of patients with gastroparesis?

The following **PICOs** were used to select literature to inform this review.

Populations

The relevant population of interest are patients with gastroparesis.

Interventions

The therapy being considered is gastric POEM (G-POEM). The G-POEM procedure involves tunneling an endoscope down the esophagus toward the esophageal-gastric junction. A surgeon performs the myotomy by cutting only the inner, circular LES muscles through a submucosal tunnel created in the proximal esophageal mucosa.

Patients receive general anesthesia during the G-POEM procedure, which is conducted in tertiary care facilities.

Comparators

Comparators of interest include diet, medications and surgical interventions.

Outcomes

The general outcomes of interest are symptom relief and treatment-related morbidity.

Systematic Reviews

Mohan et al (2019) conducted a meta-analysis to evaluate the clinical outcomes of gastric peroral endoscopic myotomy (G-POEM) and used the outcomes of surgical pyloroplasty as a comparator group in the treatment of refractory gastroparesis.⁶⁵ Three hundred and thirty-two and 375 patients underwent G-POEM (11 studies) and surgical pyloroplasty (seven studies), respectively. The pooled rate of clinical success, based on the GCSI score, with G-POEM was 75.8% (95% CI 68.1-82.1, I = 50) and with surgical pyloroplasty was 77.3% (95% CI 66.4-85.4, I = 0), with no significance, p = 0.81. The pooled rate of clinical success, based on the 4-hour GES results, with G-POEM was 85.1% (95% CI 68.9-93.7, I = 74) and with surgical pyloroplasty was 84% (95% CI 64.4-93.8, I = 81), with no significance, p = 0.91. The overall adverse events were comparable. Based on meta-regression analysis, idiopathic gastroparesis, prior treatment with botulinum toxin and gastric stimulator seemed to predict clinical success with G-POEM.

Zhang et al (2019) conducted a systematic review to assess the efficacy and safety of G-POEM for the treatment of gastroparesis.⁶⁶ The evaluation of clinical efficacy and safety was based on gastric emptying scintigraphy normalization, the improvement in clinical symptoms and adverse event rate. R 3.5.0 software was used to calculate the pooled estimate rates by meta-analysis. The improvement rate of the Gastroparesis Cardinal Symptom Index score was analyzed at different follow-up times. Fourteen studies with a total of 276 patients were included in this systematic review. The pooled gastric emptying scintigraphy normalization rate was 61.3% (95% CI, 51.5-70.8%) and clinical symptom improvement rate was 88.2% (95% CI, 83.6-93.1%). Intra-operative complications were found in about 3.2% (95% CI, 0.1-4.2%) of all included patients, and postoperative adverse events in 2.1% (95% CI, 0.3-4.8%). The mean Gastroparesis Cardinal Symptom Index score improvement rate was about 90.2% at one month follow-up, 83.3% at three months, 70.3% at six months, 52.4% at twelve months and 57.1% at eighteen months. The authors concluded that although the short-term outcomes are promising, prospective, randomized, controlled studies with large sample size and long-term follow-up are required to further confirm these results.

Ichkhanian et al (2020) studied the safety of G-POEM and described the predictive factors of adverse events occurrence (Aes).⁶⁷ This study is a retrospective study involving 13 tertiary care centers (7 USA, 1 South America, 4 Europe, and 1 Asia). Patients who underwent G-POEM for refractory gastroparesis were included. Cases were identified by the occurrence of Aes. For each case, two controls were randomly selected and matched for age (\pm 10 years), gender, and etiology of gastroparesis. A total of 216 patients underwent G-POEM for gastroparesis. Overall, 31 (14%) Aes were encountered [mild 24 (77%), moderate 5 (16%), and severe 2 (6%)] during the duration of the study. The most common AE was abdominal pain (n = 16), followed by mucosotomy (n = 5) and capnoperitoneum (n = 4), and Aes were most commonly identified within the first 48-h post-procedure 18 (58%). The risk of adverse event occurrence was significantly higher for endoscopists with experience of < 20 G-POEM procedures (OR 3.03 [1.03-8.94], p < 0.05). Although this procedure appears safe prospective, randomized controlled studies and long-term follow-up are required to further confirm these results.

Section Summary: G-POEM for Patients with Gastroparesis

One systematic review and one meta-analysis available evaluating G-POEM for the treatment of gastroparesis was identified. One retrospective study involving 13 tertiary care centers was

also identified. Although the procedure appears safe for gastroparesis and the initial short-term outcomes are promising, randomized controlled trials with larger sample sizes and long-term follow-up are required.

SUMMARY OF EVIDENCE

For individuals who have achalasia who receive peroral endoscopic myotomy (POEM), the evidence includes systematic reviews of observational studies, 2 randomized controlled trials, nonrandomized comparative studies, and case series. Relevant outcomes are symptoms, functional outcomes, health status measures, resource utilization, and treatment-related morbidity. Compared with pneumatic dilation or LHM, findings from RCTs demonstrated that POEM had a similar or greater treatment success rate based on the Eckardt score and similar or fewer overall adverse event rates. However, POEM had significantly higher rates of endoscopically confirmed reflux esophagitis and more daily proton-pump inhibitor use at 24 months. An important conduct limitation of the RCTs is that blinded assessment of outcomes was not used. Given that the primary outcome was based on subjective patient report of symptoms, this is a potential source of bias. Additionally, a potential relevance limitation is that the RCTs did not include any US sites. The comparative studies have primarily reported similar outcomes for POEM and for Heller myotomy in symptom relief, as assessed by the Eckardt score. Some studies have shown shorter length of stay and less postoperative pain with POEM. However, potential imbalance in patient characteristics in these nonrandomized studies might have biased the treatment comparisons. In the case series, treatment success at short follow-up periods was reported for a high proportion of patients treated with POEM. However, the incidence of adverse events was relatively high, with POEM-specific complications, including subcutaneous emphysema, pneumothorax, and thoracic effusion, reported across studies. Additionally, a substantial proportion of patients undergoing POEM developed GERD and esophagitis and required treatment. Case series do not permit conclusions about the efficacy of POEM relative to established treatment, and long-term outcomes of the procedure are not well described in the literature. The evidence is insufficient to determine the effects of the technology on health outcomes.

For pediatric patients who have achalasia who receive POEM, the evidence includes several nonrandomized studies and a systematic review. The relevant outcomes are symptoms, functional outcomes, health status measures, resource utilization, and treatment-related morbidity. The studies reported treatment success for POEM based on decreases in Eckardt scores and LES pressure. No randomized clinical trials have been reported. The evidence is insufficient to determine the effects of the technology on health outcomes.

For patients who have gastroparesis who receive G-POEM, the evidence includes one systematic review, one meta-analysis and one retrospective study. The studies reported that the procedure was safe and somewhat effective for gastroparesis. No randomized clinical trials have been reported. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

PRACTICE GUIDELINES AND POSITION STATEMENTS

American College of Gastroenterology

In 2020, the American College of Gastroenterology issued evidence-based clinical guidelines on the diagnosis and management of achalasia.⁵⁶ The quality of the evidence and the strength of recommendations were rated based on the GRADE framework. The evidence review includes the 2 RCTs of POEM compared to LHM or pneumatic dilation. POEM was discussed as an emerging therapy and stated to have promise as an alternative to the laparoscopic approach. The guidelines further stated that randomized prospective comparison trials are needed, and the procedure should be performed in the context of clinical trials. Based on their evaluation, the College made the following recommendations:

- “In patients with achalasia who are candidates for definite therapy, PD, LHM, and POEM are comparable effective therapies for type I or type II achalasia and POEM would be a better treatment option in those with type III achalasia.”
- “We suggest that POEM or PD result in comparable symptomatic improvement in patients with types I or II achalasia.” (GRADE quality=Low, Recommendation strength=Conditional)
- “We recommend that POEM and LHM result in comparable symptomatic improvement in patients with achalasia.” (GRADE quality=Moderate; Recommendation strength=Strong)
- “We recommend that tailored POEM or LHM for type III achalasia as a more efficacious alternative disruptive therapy at the lower esophageal sphincter compared to PD.” (GRADE quality=Moderate; Recommendation strength=Strong)
- “We suggest that in patients with achalasia, POEM compared with LHM with fundoplication or PD is associated with a higher incidence of GERD.” (GRADE quality=Moderate; Recommendation strength=Strong)
- We suggest that POEM is a safe option in patients with achalasia who have previously undergone PD or LHM. (GRADE quality=Low; Recommendation strength=Strong)

American Gastroenterological Association Institute (AGA)

In 2017, the American Gastroenterological Association Institute published a clinical practice update on the use of peroral endoscopic myotomy (POEM) for the treatment of achalasia.⁵⁷ Based on expert review, the Institute made the following recommendations:

- POEM should be performed by experienced physicians in high-volume centers (competence achieved after an estimated 20 to 40 procedures)
- If expertise is available, POEM should be considered primary therapy for type III achalasia
- If expertise is available, POEM should be considered comparable to Heller myotomy for any achalasia syndromes
- Patients receiving POEM should be considered high risk to develop reflux esophagitis and be advised of management considerations (e.g., proton pump inhibitor therapy and/or surveillance endoscopy) prior to undergoing POEM

American Society of Gastrointestinal and Endoscopic Surgeons

In 2020, ASGE issued an evidence-based guideline on the management of achalasia.⁶² The methodologic quality of systematic reviews was assessed using the Methodological Quality of Systematic Reviews-2 (AMSTAR-2) tool and the certainty of the body of evidence was rated as very low to high based on the GRADE framework. ASGE rated the strength of individual recommendations based on the aggregate evidence quality and an assessment of the

anticipated benefits and harms. ASGE used the phrase "we suggest" to indicate weaker recommendations and "we recommend" to indicate stronger recommendations. This guideline did not include either of the 2 available RCTs of POEM. Based on their evaluation, ASGE issued the following recommendations:

- "We suggest POEM as the preferred treatment for management of patients with type III achalasia." (Very low quality evidence)
- "In patients with failed initial myotomy (POEM or laparoscopic Heller myotomy), we suggest PD or redo myotomy using either the same or an alternative myotomy technique (POEM or laparoscopic Heller myotomy)." (Very low quality evidence)
- "We suggest that patients undergoing POEM are counseled regarding the increased risk of postprocedure reflux compared with PD and laparoscopic Heller myotomy. Based on patient preferences and physician expertise, post procedure management options include objective testing for esophageal acid exposure, long-term acid suppressive therapy, and surveillance upper endoscopy." (Low quality evidence)
- We suggest that POEM and laparoscopic Heller myotomy are comparable treatment options for management of patients with achalasia types I and II, and the treatment option should be based on shared decision-making between the patient and provider." (Low quality evidence)

These 2020 ASGE guidelines were endorsed by the American Neurogastroenterology and Motility Society and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).

International Society for Diseases of the Esophagus

In 2018, the International Society for Diseases of the Esophagus published guidelines on the diagnosis and management of achalasia.⁵⁸ The Society convened 51 experts from 11 countries, including several from the United States, to systematically review evidence, assess recommendations using the GRADE system, and vote to integrate the recommendations into the guidelines (>80% approval required for inclusion). Table 5 summarizes POEM recommendations.

Table 8. Recommendations for the Treatment of Achalasia

Recommendation	LOR	GOR
POEM is an effective therapy for achalasia both in short- and medium-term follow-up with results comparable to Heller myotomy.	Conditional	Very Low
POEM is an effective therapy for achalasia both in short- and medium-term follow-up with results comparable to pneumatic dilations.	Conditional	Low
Pretreatment information on GERD, nonsurgical options (pneumatic dilation), and surgical options with lower GERD risk (Heller myotomy) should be provided to patient.	Good practice	BCBSM
POEM is feasible and effective for symptom relief in patients previously treated with endoscopic therapies.	Conditional	Very Low
POEM may be considered an option for treating recurrent symptoms after laparoscopic Heller myotomy	Conditional	Low
Appropriate training (in vivo/in vitro animal model) and proctorship should be considered prior to a clinical program of POEM.	Good practice	BCBSM

GERD: gastroesophageal reflux disease; GOR: grade of recommendation; LOR: level of recommendation; BCBSM: not applicable; POEM: peroral endoscopic myotomy

Society of American Gastrointestinal and Endoscopic Surgeons

In 2020, SAGES endorsed the guideline on the management of achalasia issued by ASGE (2020) as described above.⁶²

In 2021, SAGES issued its own evidence-based guidelines for the use of POEM for the treatment of achalasia.⁶⁴ The expert panel agreed on 4 recommendations for adults and children with achalasia. These include:

- The panel suggests that adult and pediatric patients with type I and II achalasia may be treated with either POEM or LHM based on surgeon and patient's shared decision making (conditional recommendation; very low certainty evidence).
- The panel suggests POEM over LHM for type III adult or pediatric achalasia. (expert opinion)
- The panel recommends POEM over PD in patients with achalasia (strong recommendation, moderate certainty evidence)
- For the subgroup of patients who are particularly concerned about the continued use of proton pump inhibitors post-operatively, the panel suggests that either POEM or PD can be used based on joint patient and surgeon decision-making (conditional recommendation, very low certainty evidence)

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 6.

Table 9. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT01601678	Endoscopic vs. laparoscopic myotomy for treatment of idiopathic achalasia: a randomized, controlled trial	240	Dec 2019
NCT01832779	Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy (POEM)	600	Dec 2022
NCT01793922	A prospective randomized multi-center study comparing endoscopic pneumatic dilation and peroral endoscopic myotomy (POEM) as treatment of idiopathic achalasia	150	Jan 2023
NCT04349670	Safety and efficacy of GPOEM in the treatment of gastroparesis	40	Apr 2025
NCT03356067	Endoscopic pyloromyotomy for refractory gastroparesis (GREG)	86	Nov 2024
Unpublished			
BCBSM01402518	Observational Study of the Per-oral Endoscopic Motomy (POEM) Procedure	100	Nov 2019
NCT03228758	Efficacy of Anterior Versus Posterior Myotomy Approach in Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia – a Single Operator Analysis	290	Nov 2019
NCT02138643	Laparoscopy Heller Myotomy with Fundoplication Associated vs. Peroral Endoscopic Myotomy (POEM)	30	Dec 2017 (ongoing)

NCT: national clinical trial

Government Regulations

National/Local:

There is no national coverage determination or local (Michigan) coverage determination on this topic.

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Gastric Electrical Stimulation
-

References

1. Cheatham JG, Wong RK. Current approach to the treatment of achalasia. *Curr Gastroenterol Rep.* Jun 2011; 13(3): 219-25. PMID 21424734
2. Pandolfino JE, Kahrilas PJ. Presentation, diagnosis, and management of achalasia. *Clin Gastroenterol Hepatol.* Aug 2013; 11(8): 887-97. PMID 23395699
3. Yaghoobi M, Mayrand S, Martel M, et al. Laparoscopic Heller's myotomy versus pneumatic dilation in the treatment of idiopathic achalasia: a meta-analysis of randomized, controlled trials. *Gastrointest Endosc.* Sep 2013; 78(3): 468-75. PMID 23684149
4. Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. *Endoscopy.* Apr 2010; 42(4): 265-71. PMID 20354937
5. Hungness ES, Teitelbaum EN, Santos BF, et al. Comparison of perioperative outcomes between peroral esophageal myotomy (POEM) and laparoscopic Heller myotomy. *J Gastrointest Surg.* Feb 2013; 17(2): 228-35. PMID 23054897
6. Eckardt AJ, Eckardt VF. Treatment and surveillance strategies in achalasia: an update. *Nat Rev Gastroenterol Hepatol.* Jun 2011; 8(6): 311-9. PMID 21522116
7. Li H, Peng W, Huang S, et al. The 2 years' long-term efficacy and safety of peroral endoscopic myotomy for the treatment of achalasia: a systematic review. *J Cardiothorac Surg.* Jan 03 2019; 14(1): 1. PMID 30606216
8. Crespin OM, Liu LWC, Parmar A, et al. Safety and efficacy of POEM for treatment of achalasia: a systematic review of the literature. *Surg Endosc.* May 2017; 31(5): 2187-2201. PMID 27633440
9. Akintoye E, Kumar N, Obaitan I, et al. Peroral endoscopic myotomy: a meta-analysis. *Endoscopy.* Dec 2016; 48(12): 1059-1068. PMID 27617421
10. Patel K, Abbassi-Ghadi N, Markar S, et al. Peroral endoscopic myotomy for the treatment of esophageal achalasia: systematic review and pooled analysis. *Dis Esophagus.* Oct 2016; 29(7): 807-819. PMID 26175119
11. Andolfi C, Fisichella PM. Meta-analysis of clinical outcome after treatment for achalasia based on manometric subtypes. *Br J Surg.* Mar 2019; 106(4): 332-341. PMID 30690706

12. Dirks RC, Kohn GP, Slater B, et al. Is peroral endoscopic myotomy (POEM) more effective than pneumatic dilation and Heller myotomy? A systematic review and meta-analysis. *Surg Endosc.* May 2021; 35(5): 1949-1962. PMID 33655443
13. Facciorusso A, Singh S, Abbas Fehmi SM, et al. Comparative efficacy of first-line therapeutic interventions for achalasia: a systematic review and network meta-analysis. *Surg Endosc.* Aug 2021; 35(8): 4305-4314. PMID 32856150
14. Martins RK, Ribeiro IB, DE Moura DTH, et al. PERORAL (POEM) OR SURGICAL MYOTOMY FOR THE TREATMENT OF ACHALASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. *Arq Gastroenterol.* Jan-Mar 2020; 57(1): 79-86. PMID 32294740
15. Aiolfi A, Bona D, Riva CG, et al. Systematic Review and Bayesian Network Meta-Analysis Comparing Laparoscopic Heller Myotomy, Pneumatic Dilatation, and Peroral Endoscopic Myotomy for Esophageal Achalasia. *J Laparoendosc Adv Surg Tech A.* Feb 2020; 30(2): 147-155. PMID 31364910
16. Schlottmann F, Lockett DJ, Fine J, et al. Laparoscopic Heller Myotomy Versus Peroral Endoscopic Myotomy (POEM) for Achalasia: A Systematic Review and Meta-analysis. *Ann Surg.* Mar 2018; 267(3): 451-460. PMID 28549006
17. Awaiz A, Yunus RM, Khan S, et al. Systematic Review and Meta-Analysis of Perioperative Outcomes of Peroral Endoscopic Myotomy (POEM) and Laparoscopic Heller Myotomy (LHM) for Achalasia. *Surg Laparosc Endosc Percutan Tech.* Jun 2017; 27(3): 123-131. PMID 28472017
18. Teitelbaum EN, Soper NJ, Santos BF, et al. Symptomatic and physiologic outcomes one year after peroral esophageal myotomy (POEM) for treatment of achalasia. *Surg Endosc.* Dec 2014; 28(12): 3359-65. PMID 24939164
19. Ujiki MB, Yetasook AK, Zapf M, et al. Peroral endoscopic myotomy: A short-term comparison with the standard laparoscopic approach. *Surgery.* Oct 2013; 154(4): 893-7; discussion 897-900. PMID 24074429
20. Von Renteln D, Fuchs KH, Fockens P, et al. Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study. *Gastroenterology.* Aug 2013; 145(2): 309-11.e1-3. PMID 23665071
21. Bhayani NH, Kurian AA, Dunst CM, et al. A comparative study on comprehensive, objective outcomes of laparoscopic Heller myotomy with per-oral endoscopic myotomy (POEM) for achalasia. *Ann Surg.* Jun 2014; 259(6): 1098-103. PMID 24169175
22. Vigneswaran Y, Yetasook AK, Zhao JC, et al. Peroral endoscopic myotomy (POEM): feasible as reoperation following Heller myotomy. *J Gastrointest Surg.* Jun 2014; 18(6): 1071-6. PMID 24658904
23. Kumagai K, Tsai JA, Thorell A, et al. Per-oral endoscopic myotomy for achalasia. Are results comparable to laparoscopic Heller myotomy?. *Scand J Gastroenterol.* May 2015; 50(5): 505-12. PMID 25712228
24. Kumbhari V, Tieu AH, Onimaru M, et al. Peroral endoscopic myotomy (POEM) vs laparoscopic Heller myotomy (LHM) for the treatment of Type III achalasia in 75 patients: a multicenter comparative study. *Endosc Int Open.* Jun 2015; 3(3): E195-201. PMID 26171430
25. Teitelbaum EN, Soper NJ, Pandolfino JE, et al. Esophagogastric junction distensibility measurements during Heller myotomy and POEM for achalasia predict postoperative symptomatic outcomes. *Surg Endosc.* Mar 2015; 29(3): 522-8. PMID 25055891
26. Chan SM, Wu JC, Teoh AY, et al. Comparison of early outcomes and quality of life after laparoscopic Heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia. *Dig Endosc.* Jan 2016; 28(1): 27-32. PMID 26108140

27. Sanaka MR, Hayat U, Thota PN, et al. Efficacy of peroral endoscopic myotomy vs other achalasia treatments in improving esophageal function. *World J Gastroenterol*. May 28 2016; 22(20): 4918-25. PMID 27239118
28. Schneider AM, Louie BE, Warren HF, et al. A Matched Comparison of Per Oral Endoscopic Myotomy to Laparoscopic Heller Myotomy in the Treatment of Achalasia. *J Gastrointest Surg*. Nov 2016; 20(11): 1789-1796. PMID 27514392
29. Khashab MA, Kumbhari V, Tieu AH, et al. Peroral endoscopic myotomy achieves similar clinical response but incurs lesser charges compared to robotic heller myotomy. *Saudi J Gastroenterol*. Mar-Apr 2017; 23(2): 91-96. PMID 28361839
30. Leeds SG, Burdick JS, Ogola GO, et al. Comparison of outcomes of laparoscopic Heller myotomy versus per-oral endoscopic myotomy for management of achalasia. *Proc (Bayl Univ Med Cent)*. Oct 2017; 30(4): 419-423. PMID 28966450
31. de Pascale S, Repici A, Puccetti F, et al. Peroral endoscopic myotomy versus surgical myotomy for primary achalasia: single-center, retrospective analysis of 74 patients. *Dis Esophagus*. Aug 01 2017; 30(8): 1-7. PMID 28575245
32. Peng L, Tian S, Du C, et al. Outcome of Peroral Endoscopic Myotomy (POEM) for Treating Achalasia Compared With Laparoscopic Heller Myotomy (LHM). *Surg Laparosc Endosc Percutan Tech*. Feb 2017; 27(1): 60-64. PMID 28145968
33. Ward MA, Gitelis M, Patel L, et al. Outcomes in patients with over 1-year follow-up after peroral endoscopic myotomy (POEM). *Surg Endosc*. Apr 2017; 31(4): 1550-1557. PMID 27858209
34. Hanna AN, Datta J, Ginzberg S, et al. Laparoscopic Heller Myotomy vs Per Oral Endoscopic Myotomy: Patient-Reported Outcomes at a Single Institution. *J Am Coll Surg*. Apr 2018; 226(4): 465-472.e1. PMID 29410262
35. Ramirez M, Zubieta C, Ciotola F, et al. Per oral endoscopic myotomy vs. laparoscopic Heller myotomy, does gastric extension length matter?. *Surg Endosc*. Jan 2018; 32(1): 282-288. PMID 28660419
36. Caldaro T, Familiari P, Romeo EF, et al. Treatment of esophageal achalasia in children: Today and tomorrow. *J Pediatr Surg*. May 2015; 50(5): 726-30. PMID 25783358
37. Fumagalli U, Rosati R, De Pascale S, et al. Repeated Surgical or Endoscopic Myotomy for Recurrent Dysphagia in Patients After Previous Myotomy for Achalasia. *J Gastrointest Surg*. Mar 2016; 20(3): 494-9. PMID 26589525
38. Greenleaf EK, Winder JS, Hollenbeak CS, et al. Cost-effectiveness of per oral endoscopic myotomy relative to laparoscopic Heller myotomy for the treatment of achalasia. *Surg Endosc*. Jan 2018; 32(1): 39-45. PMID 29218664
39. Kim GH, Jung KW, Jung HY, et al. Superior clinical outcomes of peroral endoscopic myotomy compared with balloon dilation in all achalasia subtypes. *J Gastroenterol Hepatol*. Apr 2019; 34(4): 659-665. PMID 30695124
40. Meng F, Li P, Wang Y, et al. Peroral endoscopic myotomy compared with pneumatic dilation for newly diagnosed achalasia. *Surg Endosc*. Nov 2017; 31(11): 4665-4672. PMID 28411346
41. Miller HJ, Neupane R, Fayeziadeh M, et al. POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia. *Surg Endosc*. Apr 2017; 31(4): 1636-1642. PMID 27534662
42. Ponds FA, Fockens P, Lei A, et al. Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naive Patients With Achalasia: A Randomized Clinical Trial. *JAMA*. Jul 09 2019; 322(2): 134-144. PMID 31287522

43. Sanaka MR, Thota PN, Parikh MP, et al. Peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic Heller myotomy in achalasia. *Surg Endosc.* Jul 2019; 33(7): 2284-2292. PMID 30341655
44. Wang X, Tan Y, Lv L, et al. Peroral endoscopic myotomy versus pneumatic dilation for achalasia in patients aged 65 years. *Rev Esp Enferm Dig.* Oct 2016; 108(10): 637-641. PMID 27649684
45. Werner YB, Hakanson B, Martinek J, et al. Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia. *N Engl J Med.* Dec 05 2019; 381(23): 2219-2229. PMID 31800987
46. Wirsching A, Boshier PR, Klevebro F, et al. Comparison of costs and short-term clinical outcomes of per-oral endoscopic myotomy and laparoscopic Heller myotomy. *Am J Surg.* Oct 2019; 218(4): 706-711. PMID 31353034
47. Zheng Z, Zhao C, Su S, et al. Peroral endoscopic myotomy versus pneumatic dilation - result from a retrospective study with 1-year follow-up. *Z Gastroenterol.* Mar 2019; 57(3): 304-311. PMID 30861554
48. Podboy AJ, Hwang JH, Rivas H, et al. Long-term outcomes of per-oral endoscopic myotomy compared to laparoscopic Heller myotomy for achalasia: a single-center experience. *Surg Endosc.* Feb 2021; 35(2): 792-801. PMID 32157405
49. Tan Y, Zhu H, Li C, et al. Comparison of peroral endoscopic myotomy and endoscopic balloon dilation for primary treatment of pediatric achalasia. *J Pediatr Surg.* Oct 2016; 51(10): 1613-8. PMID 27339081
50. Boeckxstaens GE, Annese V, des Varannes SB, et al. Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. *N Engl J Med.* May 12 2011; 364(19): 1807-16. PMID 21561346
51. Borges AA, Lemme EM, Abrahao LJ, et al. Pneumatic dilation versus laparoscopic Heller myotomy for the treatment of achalasia: variables related to a good response. *Dis Esophagus.* Jan 2014; 27(1): 18-23. PMID 23551592
52. Kostic S, Kjellin A, Ruth M, et al. Pneumatic dilatation or laparoscopic cardiomyotomy in the management of newly diagnosed idiopathic achalasia. Results of a randomized controlled trial. *World J Surg.* Mar 2007; 31(3): 470-8. PMID 17308851
53. Hamdy E, El Nakeeb A, El Hanfy E, et al. Comparative Study Between Laparoscopic Heller Myotomy Versus Pneumatic Dilatation for Treatment of Early Achalasia: A Prospective Randomized Study. *J Laparoendosc Adv Surg Tech A.* Jun 2015; 25(6): 460-4. PMID 25951417
54. Zhong C, Tan S, Huang S, et al. Peroral endoscopic myotomy versus pneumatic dilation for achalasia: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol.* Nov 2020; 32(11): 1413-1421. PMID 32516175
55. Docimo S, Mathew A, Shope AJ, et al. Reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic Heller myotomy. *Surg Endosc.* Feb 2017; 31(2): 795-800. PMID 27338580
56. Zhong C, Tan S, Huang S, et al. Clinical outcomes of peroral endoscopic myotomy for achalasia in children: a systematic review and meta-analysis. *Dis Esophagus.* Apr 07 2021; 34(4). PMID 33316041
57. Lee Y, Brar K, Doumouras AG, et al. Peroral endoscopic myotomy (POEM) for the treatment of pediatric achalasia: a systematic review and meta-analysis. *Surg Endosc.* Jun 2019; 33(6): 1710-1720. PMID 30767141
58. Nabi Z, Ramchandani M, Chavan R, et al. Outcome of peroral endoscopic myotomy in children with achalasia. *Surg Endosc.* Nov 2019; 33(11): 3656-3664. PMID 30671667

59. Miao S, Wu J, Lu J, et al. Peroral Endoscopic Myotomy in Children With Achalasia: A Relatively Long-term Single-center Study. *J Pediatr Gastroenterol Nutr.* Feb 2018; 66(2): 257-262. PMID 28691974
60. Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. *Am J Gastroenterol.* Sep 2020; 115(9): 1393-1411. PMID 32773454
61. Kahrilas PJ, Katzka D, Richter JE. Clinical Practice Update: The Use of Per-Oral Endoscopic Myotomy in Achalasia: Expert Review and Best Practice Advice From the AGA Institute. *Gastroenterology.* Nov 2017; 153(5): 1205-1211. PMID 28989059
62. Khashab MA, Vela MF, Thosani N, et al. ASGE guideline on the management of achalasia. *Gastrointest Endosc.* Feb 2020; 91(2): 213-227.e6. PMID 31839408
63. Zaninotto G, Bennett C, Boeckxstaens G, et al. The 2018 ISDE achalasia guidelines. *Dis Esophagus.* Sep 01 2018; 31(9). PMID 30169645
64. Kohn GP, Dirks RC, Ansari MT, et al. SAGES guidelines for the use of peroral endoscopic myotomy (POEM) for the treatment of achalasia. *Surg Endosc.* May 2021; 35(5): 1931-1948. PMID 33564964
65. Mohan BP, Chandan S, Jha LK, et al. Clinical efficacy of gastric peroral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. *Surg Endosc.* Oct 3 2019. [Epub ahead of print].
66. Zhang H, Zhang J, Jiang A and Ni H. Gastric peroral endoscopic myotomy for gastroparesis: a systematic review of efficacy and safety. *Gastroenterol Hepatol.* Aug-Sept 2019;42(7):413-422.
67. Ichkhanian Y, Vosoughi K, Aghaie Meybodi, M, et al. Comprehensive analysis of adverse events associated with gastric peroral endoscopic myotomy: an international multicenter study. *Surg Endosc.* Apr 23 2020. [Epub ahead of print].
68. Blue Cross Blue Shield Association. Peroral Endoscopic Myotomy for Treatment of Esophageal Achalasia. Medical Policy Reference Manual. Policy # 2.01.91, original policy date 11/09/13, last review date December 2023.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through January 2024, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
9/1/16	6/21/16	7/12/16	Joint policy established
9/1/17	6/20/17	6/20/17	Updated background and rationale sections, added the following references 6-8, 10, 11, 16 and 17. No change in policy status.
9/1/18	6/19/18	6/19/18	Updated rationale, added reference #28. No change in policy status.
9/1/19	6/18/19		Policy updated with literature review through September 4, 2018; reference 9, 19, 30, and 34 added. Policy statement unchanged.
9/1/20	6/16/20		Updated rationale section, added references # 7, 15-18, 35-37 and 43-46. Added "Pediatric and Adult" and "gastroparesis" to MPS.
9/1/21	6/15/21		Updated rationale section, added references #12, 13, 38. No change in policy status.
5/1/22	2/15/22		Added code 43497
5/1/23	2/21/23		Rationale updated, several references added. No change in policy status. (ds)
5/1/24	2/20/24		Routine policy maintenance, meeting with provider regarding G-POEM, no change in policy status. Vendor managed: N/A (ds)

Next Review Date: 2nd Qtr. 2025

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: PERORAL ENDOSCOPIC MYOTOMY FOR TREATMENT OF ESOPHAGEAL
ACHALASIA OR GASTROPARESIS

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Not covered.
BCNA (Medicare Advantage)	See government section.
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.